The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis Ilaris for use in acute gouty arthritis patients who are not suitable for current treatments.
The only approved entirely human monoclonal antibody Ilaris continuously neutralizes interleukin-1 beta thereby inhibiting inflammation.
Novartis division head David Epstein said, "When approved, lIaris will provide a new treatment option for patients who have endured frequent and crippling gouty arthritis attacks and where existing therapies do not offer relief."
If approved, Ilaris will be indicated for adult patients with frequent gouty arthritis attacks and provide pain relief by means of a 150mg single subcutaneous injection.
